PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces
- Conditions
- Prostatic Neoplasms
- Interventions
- Drug: Novel hormonal therapy
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1000
- Registration Number
- NCT06151418
- Locations
- 🇺🇸
Pfizer Inc, New York, New York, United States
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 492
- Registration Number
- NCT06152575
- Locations
- 🇫🇷
Hôpital NOVO, Pontoise, Val-d'oise, France
🇺🇸Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Beverly Hills Cancer Center, Beverly Hills, California, United States
A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT06140290
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo for PF-07868489
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT06137742
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
A Study to Learn About the Study Medication, Zavegepant, in Healthy Volunteers
- Conditions
- Biological Availability
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT06137703
- Locations
- 🇺🇸
Syneos Health Clinical Research Services, Llc, Miami, Florida, United States
A Study to Learn How the Study Medicine PF-07899895 Are Tolerated and Act in the Body of Healthy Adults
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT06137729
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
Special Investigation for Booster Dose of Comirnaty in Children Ages 6 Months Though 4 Years
- Conditions
- COVID-19SARS-CoV-2
- Interventions
- Biological: COMIRNATY intramuscular injection
- First Posted Date
- 2023-11-14
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT06130410
- Locations
- 🇯🇵
Pfizer Local Country, Tokyo, Japan
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT06125522
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸UCHealth Harmony, Fort Collins, Colorado, United States
A Study to Learn PF-07817883 Blood Levels After Administration of Tablets of Study Drug to Healthy Adult Volunteers
- Conditions
- Healthy
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT06122194
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Phase 2 Study to Learn About a Monovalent Pneumococcal Conjugate Candidate in Healthy Toddlers
- Conditions
- Healthy Participants
- Interventions
- Biological: mPnC candidateBiological: mPnC control
- First Posted Date
- 2023-11-03
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 105
- Registration Number
- NCT06116591
- Locations
- 🇫🇮
FVR, Kokkolan rokotetutkimusklinikka, Kokkola, Mellersta Österbotten, Finland
🇫🇮FVR, Tampereen rokotetutkimusklinikka, Tampere, Pirkanmaa, Finland
🇫🇮FVR, Oulun rokotetutkimusklinikka, Oulu, Pohjois-pohjanmaa, Finland